title: [Alfa-2a interferon induces molecular remission in post-BMT relapse of chronic myelogenous leukaemia. Report of a case with loss of bcr-abl RNA].
abstract: Alpha-interferon (alpha-IFN) has been used in relapsed CML post-BMT, cytogenetic responses being attained in a number of cases (33 to 42%). In first chronic phase-CML patients such cytogenetic response has been correlated with the disappearance of the bcr region rearrangement, as seen with Southern-blot, but when RT-PCR is used only a small number of patients maintain undetectable traces of the Ph1 clone. A case of CML in haematological and cytogenetic relapse after BMT is reported who showed criteria of "accelerated" phase and, after treatment with alpha-IFN achieved haematologic, cytogenetic and molecular remission (Southern-blot and PCR negative) and disappearance of the abnormal clone with recovery of the donor haemopoiesis. The duration of the alpha-IFN cytogenetic response is longer than that of BMT (5 vs 3.5 yr), which is noteworthy. Taking the low toxicity of alpha-IFN into account, as compared with that of the other choices (a second BMT, IL2), this treatment should be offered to all patients with cytogenetic relapse after BMT.
authors.affiliation: Servicio de Hematología y Hemoterapia, Hospital Universitario de la Princesa.
authors.forename: L F
authors.initials: LF
authors.lastname: Casado
authors.forename: J L
authors.initials: JL
authors.lastname: Steegmann
authors.forename: M
authors.initials: M
authors.lastname: Picó
authors.forename: M J
authors.initials: MJ
authors.lastname: Requena
authors.forename: C
authors.initials: C
authors.lastname: Gómez
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández-Rañada
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015139:Blotting, Southern; D016026:Bone Marrow Transplantation; D005260:Female; D015321:Gene Rearrangement; D016313:Genes, abl / Q000235:genetics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012313:RNA / Q000032:analysis; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012313:RNA
vernacular_title: El interferón alfa 2a induce remisiones moleculares en las recaídas post-TMO de la leucemia mieloide crónica. Descripción de un caso con desaparición del ARN bcr-abl.